Proteolysis-targeting chimeras (PROTACs) are heterobifunctional molecules consisting of
one ligand that binds to a protein of interest (POI) and another that can recruit an E3 …

Abstract PROteolysis TArgeting Chimeras (PROTACs) technology is a new protein-
degradation strategy that has emerged in recent years. It uses bifunctional small molecules …

Abstract PROteolysis TArgeting Chimeras (PROTACs) has been exploited to degrade
putative protein targets. However, the antitumor performance of PROTACs is impaired by …

Protease inhibitors can modulate intratumoral metabolic processes to reprogram the
immunosuppressive tumor microenvironment (TME), which however suffer from the limited …

Although proteolysis targeting chimeras (PROTACs) have become promising therapeutic
modalities, important concerns exist about the potential toxicity of the approach owing to …

Proteolysis targeting chimera (PROTAC) is an emerging protein degradation strategy, which
shows excellent advantages in targeting those so-called “undruggable” proteins. However …

Confining the protein degradation activity of proteolysis-targeting chimera (PROTAC) to
cancer lesions ensures precision treatment. However, it still remains challenging to precisely …

The selective removal of misfolded, aggregated, or aberrantly overexpressed protein plays
an essential role in maintaining protein-dominated biological processes. In parallel, the …

Proteolysis targeting chimera (PROTAC) technology, one of the targeted protein degradation
technologies, has drawn marked attention from researchers of both academia and industry …

Proteolysis Targeting Chimeras (PROTACs), an emerging therapeutic entity designed to
degrade target proteins by hijacking the ubiquitin–proteasome system, have the potential to …